The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Vaccines comprising innovative adjuvants are rapidly reaching advanced translational
stages, such as the authorized nanotechnology adjuvants in mRNA vaccines against COVID …

Antigen cross-presentation, wherein dendritic cells (DCs) present exogenous antigen on
major histocompatibility class I (MHC-I) molecules, is considered the primary mechanism by …

Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such
as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of …

Dendritic cells are at the center of immune responses. They are defined by their ability to
sense the environment, take up and process antigen, migrate to secondary lymphoid …

Phagocytes, particularly dendritic cells (DCs), generate peptide-major histocompatibility
complex (MHC) I complexes from antigens they have collected from cells in tissues and …

Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells,
current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity …

In the late 1980s and early 1990s, the hunt for a transporter molecule ostensibly responsible
for the translocation of peptides across the endoplasmic reticulum (ER) membrane yielded …

Adjuvant, as an important part of vaccines, can observably enhance the magnitude, breadth
and durability of immune responses. Nanoadjuvants, as novel vaccine adjuvants, have …

Human leukocyte antigen (HLA) class I antigen-processing machinery (APM) plays a crucial
role in the synthesis and expression of HLA class I tumor antigen-derived peptide …